Taysha IPO Presentation Deck

Unparalleled gene therapy pipeline focused exclusively on monogenic CNS disorders PROGRAM NEURODEGENERATIVE DISEASES TSHA-101 GRT TSHA-118/ ABO-202 GRT TSHA-104 GRT TSHA-112 GRT/miRNA TSHA-111 GRT/MURNA TSHA-119 MIRNA TSHA-115 mIRNA TSHA-102 Regulated GRT TSHA-106 shANA TSHA-116 shANA TSHA-117 Regulated GRT TSHA-107 GAT TSHA-108 GRT TSHA-109 GAT GENETIC EPILEPSILS TSHA-103 GRT TSHA-105 GRT NEURODEVELOPMENTAL DISORDERS TSHA-110 GAT GM2 Gangliosidosis CLN1 SURF1 Deficiency Lafora Tauopathies GSD INDICATION Rett Syndrome Angelman Syndrome Fragile X Syndrome Prader-Willi Syndrome FOXG1 Syndrome Autism Spectrum Disorder Inborn Error of Metabolism Inherited Metabolism Disorder SLC6A1 SLC13AS KONO DISCOVERY PRECLINICAL PHASE 1/2 CTA submission 2020 Currently open IND IND submission 2021 IND submission 2021 IND submission 2021 PHASE 2/3 GLOBAL COMMERCIAL RIGHTS TAYSHA TAYSHA TAYSHA *Option rights **Taysha has exclusive options to acquire an additional four programs from UT Southwestern GRT: Gene replacement therapy miRNA: microRNA shRNA: short hairpin RNA

View entire presentation